For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Altria Group, Inc. (MO) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Watch · Gem Score +28 (−100…+100 Quality+Value blend) · Quality 33 · Value 25 · Sentiment -7 (timing only, not weighted) · Composite fair value $75.92 vs $68.65 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Altria Group, Inc.
MO NYSEAltria Group, Inc. is a holding company that manufactures and sells smokeable and oral tobacco products primarily in the United States. It operates through key subsidiaries including Philip Morris USA, which produces and markets cigarettes under the leading Marlboro brand; U.S. Smokeless Tobacco, offering moist smokeless tobacco products like Copenhagen and Skoal; John Middleton, specializing in machine-made large cigars and pipe tobacco under the Black & Mild brand; and Helix Innovations, providing oral nicotine pouches under the on! brand. Additionally, the company offers e-vapor products through NJOY ACE and engages in reduced-risk categories via a joint venture with Japan Tobacco for heated tobacco. Altria Group, Inc. distributes its products to wholesalers, distributors, and large retail chains such as convenience stores and supermarkets. Beyond tobacco, it holds investments in Anheuser-Busch InBev and Cronos Group. Founded in 1919 and headquartered in Richmond, Virginia, Altria Group, Inc. plays a significant role in the U.S. consumer staples sector, particularly in the tobacco industry.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 4.12
Total Equity: -$3.45B
Shares: 1,683,000,000
Total Debt: $25.71B
Cash: $4.47B
EBITDA: $10.17B
Total Debt: $25.71B
Cash: $4.47B
Revenue: $23.28B
Revenue: $23.28B
Revenue: $23.28B
Total Equity: -$3.45B
Tax Rate: 26.0%
Equity: -$3.45B
Total Debt: $25.71B
Cash: $4.47B
Current Liabilities: $9.15B
Long-Term Debt: $24.14B
Total Debt: $25.71B
Total Equity: -$3.45B
Shares: 1,683,000,000
Shares: 1,683,000,000
CapEx: -$216.00M
Shares: 1,683,000,000
Stock Price: $68.35
Net Income: $6.95B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 7, 2026 4:36am (61d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $26.0B | $25.1B | $24.5B | $24.0B | $23.3B |
| Cost of Revenue | $12.0B | $10.9B | $10.2B | $9.7B | $8.7B |
| Gross Profit | $14.0B | $14.2B | $14.3B | $14.4B | $14.5B |
| Operating Expenses | $2.4B | $2.3B | $2.7B | $3.1B | $4.6B |
| Operating Income | $11.6B | $11.9B | $11.5B | $11.2B | $9.9B |
| Net Income | $2.5B | $5.8B | $8.1B | $11.3B | $6.9B |
| EBITDA | $11.8B | $12.1B | $11.8B | $11.5B | $10.2B |
| EPS | $1.34 | $3.19 | $4.57 | $6.54 | $4.12 |
| EPS (Diluted) | $1.34 | $3.19 | $4.57 | $6.54 | $4.12 |
Balance Sheet (Annual)
Last updated: Aug 5, 2026 9:43am (63d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.5B | $4.0B | $3.7B | $3.1B | $4.5B |
| Total Current Assets | $6.1B | $7.2B | $5.6B | $4.5B | $5.9B |
| Total Assets | $39.5B | $37.0B | $38.6B | $35.2B | $35.0B |
| Current Liabilities | $8.6B | $8.6B | $11.3B | $8.8B | $9.2B |
| Long-Term Debt | $26.9B | $25.1B | $25.1B | $23.4B | $24.1B |
| Total Liabilities | $41.1B | $40.9B | $42.1B | $37.4B | $38.5B |
| Total Equity | -$1.6B | -$3.9B | -$3.5B | -$2.2B | -$3.5B |
| Retained Earnings | $30.7B | $29.8B | $31.1B | $35.5B | $35.5B |
Cash Flow (Annual)
Last updated: Aug 7, 2026 4:36am (61d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $8.4B | $8.3B | $9.3B | $8.8B | $9.3B |
| Capital Expenditure | -$169.0M | -$205.0M | -$196.0M | -$142.0M | -$216.0M |
| Free Cash Flow | $8.2B | $8.1B | $9.1B | $8.6B | $9.1B |
| Acquisitions (net) | $0 | $0 | -$2.8B | $0 | $0 |
| Net Debt Issued / (Repaid) | -$1.1B | -$1.1B | -$568.0M | -$1.1B | $385.0M |
| Dividends Paid | -$6.4B | -$6.6B | -$6.8B | -$6.8B | -$7.0B |
| Stock Buybacks | -$1.7B | -$1.8B | -$1.0B | -$3.4B | -$1.0B |
| Net Change in Cash | -$412.0M | -$503.0M | -$370.0M | -$563.0M | $1.3B |
Growth Trends (YoY %)
Last updated: Aug 7, 2026 4:36am (61d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -3.5% | -2.4% | -1.9% | -3.1% |
| Gross Profit Growth | +1.8% | +0.3% | +0.6% | +1.2% |
| Operating Income Growth | +3.1% | -3.1% | -2.7% | -11.9% |
| Net Income Growth | +132.9% | +41.0% | +38.5% | -38.3% |
| EBITDA Growth | +2.9% | -2.7% | -2.5% | -11.8% |
Dividend History (Last 20)
Last updated: Aug 5, 2026 9:43am (63d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-15 | $1.06 | — | — | — |
| 2026-03-25 | $1.06 | — | — | — |
| 2025-12-26 | $1.06 | — | — | — |
| 2025-09-15 | $1.06 | — | — | — |
| 2025-06-16 | $1.02 | — | — | — |
| 2025-03-25 | $1.02 | — | — | — |
| 2024-12-26 | $1.02 | — | — | — |
| 2024-09-16 | $1.02 | — | — | — |
| 2024-06-14 | $0.98 | — | — | — |
| 2024-03-22 | $0.98 | — | — | — |
| 2023-12-20 | $0.98 | — | — | — |
| 2023-09-14 | $0.98 | — | — | — |
| 2023-06-14 | $0.94 | — | — | — |
| 2023-03-23 | $0.94 | — | — | — |
| 2022-12-21 | $0.94 | — | — | — |
| 2022-09-14 | $0.94 | — | — | — |
| 2022-06-14 | $0.90 | — | — | — |
| 2022-03-24 | $0.90 | — | — | — |
| 2021-12-22 | $0.90 | — | — | — |
| 2021-09-14 | $0.90 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-02 02:03A +1σ run of quarters pays -9%; a −1σ run costs 43%. Ratio -0.2:1 (μ -1.0%, σ 3.0% floored by absolute, 16 pairs).
Older method (repeat-worst-quarter): -0.3 : 1
| Case | Growth | Margin | Fair value | vs price ($68.65) |
|---|---|---|---|---|
| Bull — recovery | -0% | 35.0% | $57.66 | -16% |
| Base — stabilizes | -1% | 34.0% | $55.49 | -19% |
| Bear — keeps slipping | -1% | 28.9% | $47.44 | -31% |
| Stress — last quarter repeats | -2% | 19.9% | $33.23 | -52% |
| Upside — a +1σ run of quarters (v2) | +2% | 35.0% | $62.37 | -9% |
| Stress — a −1σ run of quarters (v2) | -4% | 26.1% | $39.30 | -43% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-30 00:27The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw numbers tell a fairly clean story before I look at the models: Altria is a shrinking-revenue, cash-gushing pricing engine. Revenue has declined every year from $26.0B (2021) to $23.3B (2025), a -2.5% CAGR, but gross profit has actually risen from $13.99B to $14.54B — pure pricing power over eroding volumes. Operating margin sits at 42.5%, FCF is $9.07B on $216M capex (2.3% capex intensity — this is a royalty stream, not an operating company), and the 6.2% dividend at a 100.2% payout ratio is the whole thesis. Negative book equity (-$3.45B) is cosmetic, a function of decades of buybacks funded by $25.7B of debt against $9.3B operating cash — leverage is manageable at ~2.5x EBITDA. The quarterly cadence looks fine: H1'26 revenue of $11.54B is actually up ~1.5% vs H1'25's $11.36B, quietly breaking the multi-year decline. The -38.3% recent earnings YoY is a noise artifact from the lumpy Q4'24 $3.04B print (likely an ABI-related gain), not operating deterioration.
On the models: the synthesis verdict of $88.44 fair value / +28.8% upside is too aggressive and I partially dissent. A DCF on a business with -2.5% revenue CAGR and terminal regulatory tail risk should not be underwriting 28% upside — that number implicitly assumes the payout ratio normalizes, smoke-free scales, and the multiple re-rates from 16.7x to ~21x. That's three bullish things happening simultaneously to a tobacco company. The pre-flight "dividend-income / cash annuity" framing is the correct lens; the narrative layer's "fallen-angel, moderate intensity, anchored" read is the most honest of the bunch — the 22% discount is doing real work pricing menthol-ban tail risk and ESG exclusion, not mispricing. The classification as mature_earner is right but understates that this is specifically a *melting ice cube with a fire hose of cash* — a different animal than a Coke or a PG.
The contrarian case a careful skeptic would push: the 100% payout ratio is the tell. Altria isn't reinvesting because there's nothing worth reinvesting in — the NJOY acquisition ($2.75B) is still unproven, the JUUL writedown was catastrophic, and the IQOS rights went back to PMI. Every dollar of "smoke-free hedge" narrative has cost shareholders real money. With payout at 100%, dividend growth has to come from either EPS growth (structurally hard when volumes decline 8-10%/year in cigarettes) or leverage (already at 2.5x on negative equity). If nicotine pouches (on!) don't scale to meaningfully offset Marlboro volume decline within 3-4 years, the dividend growth algorithm breaks and the multiple compresses to 12-13x, not expands to 21x. FDA menthol ban is a live tail — ~25% of Altria's cigarette volume is menthol. And "macro headwinds" flagged in secondary signals matters: down-trading in a weak consumer environment is real; the recent quarterly pricing/volume mix needs scrutiny that headline revenue hides.
My read: fair value is closer to $75-78, not $88. That's ~10-15% upside plus the 6.2% yield — a totally respectable total return for an income position, but not the fat pitch the synthesis implies. The methods-disagree caveat in the synthesis is doing important work; I'd weight the dividend-discount and EV/EBITDA anchors (which give something closer to current price) more than any growth-based DCF. Data quality is adequate but the Q4 earnings volatility ($1.08B → $3.04B → $1.12B swings) suggests non-operating items are polluting the trailing figures — the TTM P/E of 16.7x is probably understating the clean run-rate multiple by 1-2 turns. I'd own MO for the yield with modest capital appreciation optionality, but I would not underwrite 29% upside, and I'd be a seller into any move above $80 absent genuine smoke-free traction proof (on! shipment volumes accelerating, NJOY share gains). Partial dissent from the synthesis: right direction, wrong magnitude.
GPT Reading
What jumps out is that Altria is not a growth equity being misread by the market; it is a shrinking, very efficient cash distribution vehicle, and the key question is whether the current multiple already pays full price for that stability. The revenue line says decline, not resilience: annual sales fell from $26.01B in 2021 to $23.28B in 2025, a cumulative drop of about 10.5%, and the latest four quarters total only $23.46B versus $24.40B in the comparable prior four quarters, down roughly 3.9%. Yet gross profit held at $14.54B in 2025 versus $13.99B in 2021, which tells you the whole model still rests on formidable pricing power and mix. Operating income, however, slid from $11.24B in 2024 to $9.90B in 2025, and the quarterly pattern shows why I do not want to annualize the better 2026 first-half net income too aggressively: margins swing sharply, with net margin at 19.1% in 4Q25 and 20.5% in 1Q25 versus around 39%-40% in cleaner quarters. This is still an elite-margin business, but not one with especially clean earnings optics.
Cash flow is the strongest part of the story and the reason the stock is not obviously expensive despite secular decline. Free cash flow of $9.07B on $23.28B of revenue is a remarkable 39% FCF margin, capex is de minimis at $216M, and even against a $114.6B market cap the equity yields about 7.9% on trailing FCF before considering any change in the business. That is good, but not screamingly cheap when the revenue base is shrinking and reinvestment opportunities are limited. The balance sheet is also less comforting than headline cash generation implies: $25.71B of debt against $4.47B of cash leaves net debt above $21B, current ratio is just 0.65, and equity is negative at -$3.45B. Negative equity is not unusual for a buyback-heavy tobacco name, but it matters when the payout ratio is effectively 100% and the company is using nearly all of its earnings capacity to support the income case. At 16.7x earnings and 13.4x EV/EBITDA, I do not see a distressed annuity; I see a well-understood defensive compound payer priced roughly where it should be if the decline remains orderly.
That is why I part company with the more bullish fair-value outputs calling for something like high-$80s. To justify a move from $68.65 to $86, you need either confidence that earnings troughing in 2025 was temporary and normalized EPS can grow again, or that the market should pay a materially higher multiple for a no-growth tobacco asset than it does today. The raw data does not back either proposition. Revenue CAGR is negative 2.5%, earnings CAGR negative 7.6%, recent quarterly revenue is still down year over year, and 2025 net income of $6.95B was far below 2024’s $11.26B even allowing for one-offs in this industry. If anything, the stock today looks like a bond substitute with equity risk: a 6.2% dividend yield, sturdy cash generation, modest but persistent top-line erosion, and no evidence in the numbers provided of a smoke-free engine large enough to change the trajectory. That profile deserves a decent floor, not a growth-style rerating.
The best case against my caution is straightforward and serious. First, the latest two quarters are better than the ugly 2025 annual earnings print suggests: net income was $2.18B in 1Q26 and $2.30B in 2Q26, both roughly double the depressed prior-year quarter comps, implying earnings normalization may already be underway. Second, on cash economics the stock is not demanding. A business producing over $9B of annual FCF with almost no capex burden, 62.5% gross margins, and 42.5% operating margins can absorb a lot of volume decline before equity value truly breaks. Third, the market may still be applying an ESG and regulatory discount on top of fundamental risk; if so, 16.7x P/E for a category leader with dependable cash returns could prove too low, especially if buybacks continue to reduce the share count and prop up per-share growth despite declining aggregate revenue. If you believe 2025 was unusually depressed and 2026 can sustain something like $8B-$9B in earnings, today’s price would look more like 12x-14x normalized earnings, which is not expensive for this level of predictability.
What would change my mind is not another valuation model; it is operational proof. If the next few quarters show revenue no worse than flat to down 1%-2% year over year while net margins stay in the high-30s rather than dropping back toward 20%, I would accept that pricing power is still outrunning volume decline by enough to support a higher multiple. Likewise, if annual free cash flow holds above $9B while the dividend remains covered without leverage creeping higher, I would become more constructive. On the other hand, if trailing revenue falls through $23B, operating income stays below $10B, or net debt rises meaningfully from the current roughly $21B net level to fund payouts, the “safe income” thesis weakens fast and the stock should trade closer to a low-teens earnings multiple, which would put fair value nearer $55-$60 than $70.
Grok Reading
Altria’s numbers describe a slow-motion cash machine, not a growth story and not a collapse. Revenue has ground lower for five straight years—from $26.01B in 2021 to $23.28B in 2025, a −2.5% CAGR that matches the −3.1% recent year-over-year print—yet gross profit dollars have actually risen ($13.99B to $14.54B) because pricing continues to more than offset volume loss. That is the core operating reality: 62.5% gross margin and 42.5% operating margin on a shrinking top line. Free cash flow of $9.07B against only $216M of capex is the asset the market is really buying; at a $114.6B enterprise the FCF yield sits near 7.9%. The 2025 net income drop to $6.95B from $11.26B looks alarming (−38% earnings yoy, −7.6% earnings CAGR), but the quarterly pattern shows the damage concentrated in two soft-margin quarters (Q1 and Q4 2025 at ~19–20% NI margins). The four most recent clean quarters run $2.18–2.38B of net income, implying a ~$9B run-rate—closer to a 12.7× multiple on normalized earnings than the stated 16.7× trailing figure. Negative equity of −$3.45B and $25.7B of debt are structural artifacts of decades of buybacks and dividends, not imminent solvency stress, so long as the $9B FCF engine holds.
The dividend is the hinge. A 6.18% yield on this market cap implies roughly $7.1B of cash returned; that is covered by FCF with about $2B of headroom but sits at a 100% payout on reported 2025 earnings. That leaves little cushion if combustible volumes accelerate past the 3–5% decline already embedded in the thesis, or if another low-margin year repeats. The valuation composite pointing to $86–$88 (≈29% upside) assumes pricing power and modest smoke-free offset persist long enough to keep that FCF annuity intact. At $68.65 the stock is already discounting a harsher path—regulatory menthol risk, ESG forced selling, and skepticism that oral nicotine and e-vapor will ever replace the Marlboro cash engine at scale. I read the discount as mostly rational risk pricing plus a narrative penalty, not pure mispricing, but the cash generation still clears a higher bar than the price implies.
The strongest counter-case is straightforward: this is a sunset industry being milked. Revenue has fallen every year for five years; operating income rolled over hard in 2025 to $9.90B from $11.24B; the payout ratio above 1.0 means the dividend is already consuming the entire earnings base and will eventually force either a cut or balance-sheet stress if FCF follows earnings lower. Current ratio of 0.65 and net debt near $21B leave limited defensive flexibility. Menthol-ban tail risk and demographic exit from smoking are not fully captured by a DCF that assumes orderly 2–3% volume decay. A smart bear argues the $88 fair-value target systematically underweights those left-tail outcomes and that “undervalued” tobacco has stayed cheap for a reason—multiple compression is the equilibrium, not a temporary discount. I weigh that case seriously; I simply note that FCF has been essentially flat (−0.1% CAGR) while earnings have been noisy, and that the gross-profit dollar stability is hard to reconcile with an imminent cliff.
I would flip to a fair-or-overvalued stance if trailing-twelve-month FCF fell sustainably below ~$7.5B (breaking dividend coverage with margin), if combustible volume declines printed above 6–7% for two consecutive halves without offsetting price realization, or if a binding menthol ban or equivalent federal restriction landed with a clear volume haircut. Conversely, two clean years of smoke-free net revenue growth that visibly stabilizes consolidated revenue near $23B+ and keeps FCF ≥$8.5B would justify the re-rating the composite already assumes and push me from moderate to high conviction.
Qwen Reading local experiment · off-panel
The number that should make any analyst pause before calling this "undervalued" is the Q4 2025 net margin: 19.1%, down from 50.9% in the same quarter a year earlier, on nearly identical revenue ($5.85B vs. $5.97B). That is not a rounding error or a tax item. Whether it's a litigation settlement, a restructuring charge, or a one-time impairment, the fact that Altria's net income swung from $3.04B to $1.12B in a single quarter while revenue held steady tells you the earnings base is far more fragile than the five-year average of $6.95B implies. Layer on the -38.3% YoY earnings print and the -7.6% earnings CAGR, and the "mature earner" archetype the rule-based model assigns starts to look like a polite way of saying "the earner is losing its teeth." Revenue has fallen from $26.01B in 2021 to $23.28B in 2025 — a 10.7% erosion in four years — and the -3.1% recent YoY suggests the deceleration is not yet complete. The valuation synthesis lands at $81.82–$84.04, a 23% upside, but that composite is almost certainly built on DCF assumptions of flat-to-modestly-growing cash flows. Model $9.07B of FCF at a 2% annual decline over a decade, discount at 8%, subtract the $21.2B net debt ($25.71B debt less $4.47B cash), and you land in the low-to-mid $50s per share, not the low $80s. The market at $68.35 is not irrationally punishing Altria; it is pricing in a cash flow stream that is genuinely shrinking.
What keeps this from being a straight "overvalued" call is the sheer mechanical quality of the cash generation. $9.29B in operating cash flow against $216M of capex is almost absurdly capital-light. The 62.5% gross margin and 42.5% operating margin are the product of decades of pricing power in a category where the consumer has no real alternative. The 6.2% dividend yield is real, funded, and — for now — covered. The insider tape is unremarkable: a couple of small sales in May 2026, a batch of award grants, no panic, no conviction buying. The "fallen angel" narrative classification is the right frame. This is not a growth story with a temporary stumble; it is a cash-distribution machine whose distribution capacity is slowly eroding, and the market is correctly refusing to pay a growth multiple for it. The 16.6x P/E looks cheap next to the S&P, but it is not cheap for a business whose revenue is compounding at -2.5% and whose equity is negative $3.45B.
The strongest case against my skepticism is the FCF-to-debt coverage. At $9.07B FCF against $25.71B of total debt, Altria services its obligations roughly 3.5x over, and the current ratio of 0.648, while ugly, is less meaningful for a company that generates $9B a year in operating cash and spends almost nothing on capex. A smart opponent would point out that the Q4 2025 margin collapse is almost certainly a one-time charge — tobacco litigation settlements are lumpy, and the 2024 Q4 margin of 50.9% was itself an outlier high — and that normalizing earnings to $8–9B puts the P/E closer to 13x, which is genuinely cheap for a 6% yielder with that kind of cash conversion. They would also note that the payout ratio of 100.19% is a policy choice, not a structural constraint: Altria has the option to cut the dividend by 10–15% and still maintain a 5%+ yield while rebuilding a thin equity cushion. I weigh this differently because the negative equity position removes the optionality. A company with $3B of positive equity can absorb a bad year; a company with -$3.45B of equity is one major litigation loss or one year of accelerated volume decline away from a credit-rating conversation that would force a dividend cut regardless of management's preference. The 100%+ payout ratio is not a choice when the balance sheet has no cushion.
What would change my mind in either direction. On the bull side: if the next two quarters show net margins back above 35% (confirming Q4 2025 was a one-time charge) and management guides to flat or positive revenue growth for FY2026 — which would require the oral and heated-tobacco categories to finally contribute meaningfully beyond the single-digit percentage of revenue they represent today — I would revise toward "undervalued" and raise my price target to the low $80s. On the bear side: a dividend cut, a credit-rating downgrade below investment grade, or a Q1 2027 print showing net margins below 25% for a second consecutive quarter would confirm the structural decline is accelerating, and I would see $55 as a more honest fair value. The specific number to watch is the Q3 2026 (September) net margin: if it holds above 35%, the Q4 2025 anomaly was a one-off and the earnings base is closer to $8B than $7B. If it drops below 30%, the 2025 print was the new normal, and the 6.2% yield is on borrowed time.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Altria is a textbook mature earner: revenue drifted from $26.0B (2021) to $23.3B (2025), yet gross margin expanded from 53.8% to 62.5% and operating margin held in the mid-40s (42.5% in 2025 after mid-47s prior). FCF is remarkably steady at $8-9B annually, with OCF/NI of 1.62x and negative accruals (-4.9% of assets) confirming earnings are cash-backed. Beneish M of -2.37 and Altman Z of 4.69 show no manipulation flags and safe solvency despite the leverage.
Verify before trusting this (5)
- Whether the 2024-to-2025 net income drop reflects mark-to-market on the ABI/Cronos stakes vs. operating deterioration
- Cigarette volume decline rate vs. price-mix offset in the latest 10-K
- Debt maturity ladder and weighted average coupon given $21B+ net debt
- Progress and profitability of on! and other smoke-free/oral nicotine segments
- Any pending FDA/menthol regulatory actions materially affecting the core franchise
The composite fair value of $86.11 (signal-adjusted $88.44) sits ~26-29% above the $68.65 price. The DCF ($88.74) and anchored-PE ($117.28) both point higher, while the EPV floor at $49.66 sets a stress case roughly 28% below spot - so the market is pricing MO closer to the no-growth zombie case than to the disciplined-buyback, pricing-power case. I'd throw out the anchored-PE as too generous for a business with a shrinking top line; leaning on DCF gives a deserved value in the mid-$80s, implying ~20-25% upside plus a ~8-9% dividend while you wait. Earnings quality is high (score 3), so no haircut is warranted, and the Strong business grade supports a full multiple rather than a discount.
Verify before trusting this (5)
- Cigarette volume decline trajectory in latest 10-Q vs the 8-10% run rate
- NJOY and on! oral nicotine unit economics and share gains in transcripts
- Net debt path and any refinancing at higher rates
- Menthol ban regulatory calendar and any FDA action
- Free cash flow coverage of the dividend after capex and buybacks
MO sits at the intersection of two weak forces that largely cancel. The tape is mildly risk-on with a low VIX, but with beta 0.5 and a defensive-tobacco profile, MO barely participates in either direction; macro pressure on this name is muted. Rates at 4.67% are a soft headwind for a bond-proxy 9% yielder, but the market has already priced that in for years. The dominant force is the narrative itself: a fallen-angel tobacco story with moderate intensity and moderate durability, where the market refuses to credit the smoke-free pivot and treats the dividend as a trap. That is a persistent, low-grade de-rating pressure, not a collapse. Offsetting that, the news flow is quietly constructive: a PMI contract-manufacturing tie-up read as margin-positive, a board refresh, and a steady drumbeat of income-portfolio articles that keep MO on retail dividend shopping lists. Analyst tone in the flow is neutral-to-mildly-constructive ('reasonably priced', 'looks stronger'), and the 3-year negative price CAGR suggests sentiment is already washed out rather than actively deteriorating. Net: no dominant force in either direction, leaning very slightly negative from the sunset-industry overhang.
Verify before trusting this (4)
- Any FDA/menthol regulatory headline that could reignite the sunset narrative
- Whether smoke-free volume disclosures next quarter get credited or dismissed
- Analyst target revisions post the PMI deal
- Rotation flows in/out of high-yield defensives if the risk-on tape strengthens
The world is not abandoning nicotine, it is re-routing the delivery. Demand is migrating from combustibles toward pouches and vapor faster than Altria's smoke-free portfolio can capture, while enforcement gaps let illicit imports take switchers that should have been MO's. Altria's answer — price the loyal base, harvest cash, shrink the share count — works arithmetically for years and is genuinely underestimated at a -8.1% implied growth rate, but it is a harvesting strategy, not a growth strategy. Macro headwinds and a stressed low-income consumer are the near-term binding constraint on how far pricing can stretch; regulation is the tail. The honest shape: stable cash generation, quietly eroding units, and a structural clock that price increases delay rather than stop.
When we made this prediction on Aug 30, 2026, MO was $68.65. We expect it to be $76.20 by Mar 2027, and we consider it great value under $65.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 30, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
cost_of_capital
flips down 25%